Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for GH Research PLC (GHRS : NSDQ)
 
 • Company Description   
GH Research PLC is a clinical-stage biopharmaceutical company. It dedicated to treat psychiatric and neurological disorders. The company's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. GH Research PLC is based in DUBLIN.

Number of Employees: 50

 
 • Price / Volume Information   
Yesterday's Closing Price: $14.47 Daily Weekly Monthly
20 Day Moving Average: 186,193 shares
Shares Outstanding: 52.03 (millions)
Market Capitalization: $752.85 (millions)
Beta: 0.96
52 Week High: $20.50
52 Week Low: $6.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 12.69% 9.31%
12 Week 60.96% 39.53%
Year To Date 106.71% 95.30%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
JOSHUA DAWSON HOUSE DAWSON STREET
-
DUBLIN,L2 D02 RY95
IRL
ph: 353-1437-8334
fax: -
investors@ghres.com http://www.ghres.com
 
 • General Corporate Information   
Officers
Velichka Valcheva - Chief Executive Officer
Florian Schonharting - Chairman and Director
Michael Forer - Vice Chairman
Aaron Cameron - Chief Operating Officer
Julie Ryan - Vice President

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G3855L106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 09/02/25
Share - Related Items
Shares Outstanding: 52.03
Most Recent Split Date: (:1)
Beta: 0.96
Market Capitalization: $752.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.96 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/02/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.43
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -26.67%
vs. Previous Quarter: -11.76%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -19.20
12/31/24 - -20.06
ROA
06/30/25 - -
03/31/25 - -18.40
12/31/24 - -19.18
Current Ratio
06/30/25 - -
03/31/25 - 29.71
12/31/24 - 17.23
Quick Ratio
06/30/25 - -
03/31/25 - 29.71
12/31/24 - 17.23
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 5.96
12/31/24 - 3.44
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.10
12/31/24 - 0.21
 

Powered by Zacks Investment Research ©